TR199802676A3 - Tümörlerin, tümörle ilgili hastaliklarin ve kaseksinin tedavisi ve önlenmesi için yöntem. - Google Patents

Tümörlerin, tümörle ilgili hastaliklarin ve kaseksinin tedavisi ve önlenmesi için yöntem.

Info

Publication number: TR199802676A3
Authority: TR; Turkey
Prior art keywords: cachexia; tumors; tumor; prevention; treatment
Prior art date: 1997-12-24

Application number

TR1998/02676A

Other languages

English (en)

Other versions

TR199802676A2 (tr

Inventor

Kurakata Shinichi

Hanai Masaharu

Kanai Saori

Kimura Tomio

Original Assignee

Sankyo Company Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-24

Filing date

1998-12-23

Publication date

1999-11-22

1998-12-23 Application filed by Sankyo Company Limited filed Critical Sankyo Company Limited

1999-11-22 Publication of TR199802676A2 publication Critical patent/TR199802676A2/tr

1999-11-22 Publication of TR199802676A3 publication Critical patent/TR199802676A3/tr

Classifications

- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47G—HOUSEHOLD OR TABLE EQUIPMENT
- A47G7/00—Flower holders or the like
- A47G7/02—Devices for supporting flower-pots or cut flowers
- A47G7/04—Flower tables; Stands or hangers, e.g. baskets, for flowers
- A47G7/044—Hanging flower-pot holders, e.g. mounted on walls, balcony fences or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
- A01G5/00—Floral handling
- A01G5/04—Mountings for wreaths, or the like; Racks or holders for flowers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09F—DISPLAYING; ADVERTISING; SIGNS; LABELS OR NAME-PLATES; SEALS
- G09F23/00—Advertising on or in specific articles, e.g. ashtrays, letter-boxes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
General Physics & Mathematics (AREA)
Diabetes (AREA)
Physics & Mathematics (AREA)
Obesity (AREA)
Environmental Sciences (AREA)
Theoretical Computer Science (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyrrole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

TR1998/02676A 1997-12-24 1998-12-23 Tümörlerin, tümörle ilgili hastaliklarin ve kaseksinin tedavisi ve önlenmesi için yöntem. TR199802676A3 (tr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP35449997		1997-12-24
JP1530698		1998-01-28
JP20490798		1998-07-21
JP26944498		1998-09-24

Publications (2)

Publication Number	Publication Date
TR199802676A2 TR199802676A2 (tr)	1999-11-22
TR199802676A3 true TR199802676A3 (tr)	1999-11-22

Family

ID=27456356

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TR1998/02676A TR199802676A3 (tr)	1997-12-24	1998-12-23	Tümörlerin, tümörle ilgili hastaliklarin ve kaseksinin tedavisi ve önlenmesi için yöntem.

Country Status (21)

Country	Link
US (3)	US6887893B1 (tr)
EP (1)	EP0927555B1 (tr)
KR (2)	KR100432926B1 (tr)
CN (1)	CN1149990C (tr)
AR (1)	AR012272A1 (tr)
AT (1)	ATE527022T1 (tr)
AU (1)	AU745865B2 (tr)
BR (1)	BR9805544C1 (tr)
CA (1)	CA2257010C (tr)
CZ (1)	CZ299060B6 (tr)
DK (1)	DK0927555T3 (tr)
ES (1)	ES2372921T3 (tr)
HU (1)	HU227126B1 (tr)
ID (1)	ID21529A (tr)
IL (3)	IL143921A (tr)
NO (2)	NO317568B1 (tr)
NZ (1)	NZ333399A (tr)
PL (1)	PL193093B1 (tr)
SA (1)	SA99191102B1 (tr)
TR (1)	TR199802676A3 (tr)
TW (1)	TW562675B (tr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6703418B2 (en) *	1991-02-26	2004-03-09	Unimed Pharmaceuticals, Inc.	Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
US20040072889A1 (en)	1997-04-21	2004-04-15	Pharmacia Corporation	Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6649645B1 (en) *	1998-12-23	2003-11-18	Pharmacia Corporation	Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
JP2002533404A (ja) *	1998-12-23	2002-10-08	ジー・ディー・サール・アンド・カンパニー	新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法
CA2369145A1 (en) *	1999-06-24	2001-01-04	Pharmacia Corporation	Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation
WO2001081332A2 (en) *	2000-04-25	2001-11-01	Pharmacia Corporation	2-fluorobenzenesulfonyl compounds for the treatment of inflammation
US7115565B2 (en) *	2001-01-18	2006-10-03	Pharmacia & Upjohn Company	Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US20030087942A1 (en) *	2001-08-31	2003-05-08	Washington University	Method for the treatment and prevention of cachexia
DK1441714T3 (da) *	2001-10-25	2008-03-31	Novartis Ag	Kombinationer omfattende en selektiv cyclooxygenase-2-inhibitor
US7279576B2 (en)	2002-12-31	2007-10-09	Deciphera Pharmaceuticals, Llc	Anti-cancer medicaments
US7144911B2 (en)	2002-12-31	2006-12-05	Deciphera Pharmaceuticals Llc	Anti-inflammatory medicaments
US7202257B2 (en)	2003-12-24	2007-04-10	Deciphera Pharmaceuticals, Llc	Anti-inflammatory medicaments
WO2006071940A2 (en)	2004-12-23	2006-07-06	Deciphera Pharmaceuticals, Llc	Enzyme modulators and treatments
US8188113B2 (en)	2006-09-14	2012-05-29	Deciphera Pharmaceuticals, Inc.	Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7790756B2 (en)	2006-10-11	2010-09-07	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US20080098491A1 (en) *	2006-10-19	2008-04-24	Zoltan Laboratories Llc	Mouse models to study cachexia
CA2684950A1 (en)	2007-04-20	2008-10-30	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US8247423B2 (en) *	2007-07-12	2012-08-21	Tragara Pharmaceuticals, Inc.	Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
WO2009042612A1 (en) *	2007-09-24	2009-04-02	Tragara Pharmaceuticals, Inc.	Therapies for treating cancer using combinations of cox-2 inhibitors and aromatase inhibitors or combinations of cox-2 inhibitors and estrogen receptor antagonists
WO2009042618A1 (en) *	2007-09-24	2009-04-02	Tragara Pharmaceuticals, Inc.	Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
US20110306572A1 (en) *	2007-09-24	2011-12-15	Tragara Pharmaceuticals, Inc	COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2]
WO2009070547A1 (en) *	2007-11-28	2009-06-04	Tragara Pharmaceuticals, Inc.	Cancer treatment using cox-2 inhibitor and antimetabolite combinations
US20110301209A1 (en) *	2007-11-28	2011-12-08	Tragara Pharmaceuticals, Inc.	Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
EP2365752B1 (en)	2008-10-29	2014-09-24	Deciphera Pharmaceuticals, Llc	Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
EP2284154A1 (en)	2009-07-29	2011-02-16	Argon Pharma S.L.	Antitumor 1,2-diphenylpyrrole compounds and their preparation process
US8461179B1 (en)	2012-06-07	2013-06-11	Deciphera Pharmaceuticals, Llc	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
AU2019216351B2 (en)	2018-01-31	2024-07-25	Deciphera Pharmaceuticals, Llc	Combination therapy for the treatment of mastocytosis
CN111818915B (zh)	2018-01-31	2024-05-24	德西费拉制药有限责任公司	治疗胃肠道间质瘤的组合疗法
NZ784949A (en)	2019-08-12	2025-09-26	Deciphera Pharmaceuticals Llc	Ripretinib for treating gastrointestinal stromal tumors
TWI878335B (zh)	2019-08-12	2025-04-01	美商迪賽孚爾製藥有限公司	治療胃腸道基質瘤方法
KR20250057151A (ko)	2019-12-30	2025-04-28	데시페라 파마슈티칼스, 엘엘씨	1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의조성물
AU2020419197B2 (en)	2019-12-30	2023-08-31	Deciphera Pharmaceuticals, Llc	Amorphous kinase inhibitor formulations and methods of use thereof
US11779572B1 (en)	2022-09-02	2023-10-10	Deciphera Pharmaceuticals, Llc	Methods of treating gastrointestinal stromal tumors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4962119A (en) *	1989-06-09	1990-10-09	Warner-Lambert Company	Triazole derivatives of fenamates as antiinflammatory agents
AU6355190A (en)	1989-06-13	1991-01-17	Smithkline Beecham Corporation	Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
US5504107A (en)	1990-01-12	1996-04-02	The Ohio State University Research Foundation	Optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytetronic acids and pharmaceutical use thereof
US5208018A (en)	1990-03-19	1993-05-04	Brigham And Women's Hospital	Treatment of cachexia with interleukin 2
EP0563286A4 (en)	1990-12-13	1995-01-11	Smithkline Beecham Corp	Novel csaids
WO1992010190A1 (en)	1990-12-13	1992-06-25	Smithkline Beecham Corporation	Novel csaids
US5604260A (en) *	1992-12-11	1997-02-18	Merck Frosst Canada Inc.	5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
EP0679157B1 (en)	1993-01-15	1997-11-19	G.D. Searle & Co.	Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5380738A (en)	1993-05-21	1995-01-10	Monsanto Company	2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) *	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
FI960157L (fi)	1993-07-13	1996-01-12	Janssen Pharmaceutica Nv	Allergianvastaisia imidatsoatsepiineja
US5593991A (en)	1993-07-16	1997-01-14	Adams; Jerry L.	Imidazole compounds, use and process of making
US5344991A (en)	1993-10-29	1994-09-06	G.D. Searle & Co.	1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5466823A (en) *	1993-11-30	1995-11-14	G.D. Searle & Co.	Substituted pyrazolyl benzenesulfonamides
RO118291B1 (ro)	1993-11-30	2003-04-30	Searle & Co	Derivati de pirazol 1,3,4,5 - tetrasubstituiti si compozitie farmaceutica care ii contine
CN1143365A (zh)	1994-01-10	1997-02-19	麦克弗罗斯特(加拿大)有限公司	作为cox-2抑制剂的苯基杂环类化合物
US5418254A (en)	1994-05-04	1995-05-23	G. D. Searle & Co.	Substituted cyclopentadienyl compounds for the treatment of inflammation
JP3302178B2 (ja)	1994-06-22	2002-07-15	日本クラウンコルク株式会社	合成樹脂製容器蓋
US5486534A (en)	1994-07-21	1996-01-23	G. D. Searle & Co.	3,4-substituted pyrazoles for the treatment of inflammation
US5620999A (en)	1994-07-28	1997-04-15	Weier; Richard M.	Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en)	1994-07-28	1997-04-01	Gd Searle & Co	1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
JP2636819B2 (ja) *	1994-12-20	1997-07-30	日本たばこ産業株式会社	オキサゾール系複素環式芳香族化合物
US5593119A (en) *	1995-01-12	1997-01-14	At&T Global Information Solutions Company	Apparatus and method for mounting a terminal
ATE223390T1 (de)	1995-02-13	2002-09-15	Searle & Co	Substituierte isoxazole zur behandlung von entzündung
US5633272A (en)	1995-02-13	1997-05-27	Talley; John J.	Substituted isoxazoles for the treatment of inflammation
AU5860396A (en)	1995-05-19	1996-11-29	G.D. Searle & Co.	Substituted oxazoles for the treatment of inflammation
CA2223154A1 (en)	1995-06-02	1996-12-05	G.D. Searle & Co.	Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
CA2180624C (en)	1995-07-12	2006-12-12	Cheuk Kun Lau	Diphenyl-1,2,3-thiadiazoles as anti-inflammatory agents
GB9520584D0 (en)	1995-10-09	1995-12-13	Fujisawa Pharmaceutical Co	Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
NZ327022A (en)	1996-01-26	1999-06-29	Searle & Co	Heterocyclo-substituted imidazoles for the treatment of inflammation
JPH09323930A (ja) *	1996-04-04	1997-12-16	Takeda Chem Ind Ltd	悪液質の予防・治療剤
US5908858A (en)	1996-04-05	1999-06-01	Sankyo Company, Limited	1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
PT892791E (pt)	1996-04-12	2003-06-30	Searle & Co	N-¬¬4-(5-metil-3-fenilisoxazol-4-il\|fenil\|sulfonil-propilamida e seu sal de sodio como pro-farmacos de inibidores de cox-2
DE69717281T2 (de) *	1996-08-14	2003-09-04	G.D. Searle & Co., Chicago	Kristalline form von 4-[5-methyl-3-phenylisoxazol-4-yl]benzolsulfonamid
KR20000049138A (ko)	1996-10-15	2000-07-25	윌리암스 로저 에이	신생물의 치료 및 예방에의 시클로옥시게나제-2 저해제의 사용방법
PL194717B1 (pl)	1996-11-19	2007-06-29	Searle & Co	Zastosowanie inhibitorów cyklooksygenazy-2 do wytwarzania leku do leczenia chorób związanych z rozwojem naczyń
ES2208964T3 (es)	1996-12-10	2004-06-16	G.D. SEARLE & CO.	Compuestos de pirrolilo substituidos para el tratamiento de la inflamacion.
EP0863134A1 (en) *	1997-03-07	1998-09-09	Merck Frosst Canada Inc.	2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US5972986A (en) *	1997-10-14	1999-10-26	G.D. Searle & Co.	Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

1998
- 1998-12-16 US US09/212,556 patent/US6887893B1/en not_active Expired - Fee Related
- 1998-12-16 NZ NZ333399A patent/NZ333399A/xx not_active IP Right Cessation
- 1998-12-21 EP EP98310510A patent/EP0927555B1/en not_active Expired - Lifetime
- 1998-12-21 IL IL14392198A patent/IL143921A/xx not_active IP Right Cessation
- 1998-12-21 AT AT98310510T patent/ATE527022T1/de not_active IP Right Cessation
- 1998-12-21 IL IL12766498A patent/IL127664A/xx not_active IP Right Cessation
- 1998-12-21 ES ES98310510T patent/ES2372921T3/es not_active Expired - Lifetime
- 1998-12-21 DK DK98310510.7T patent/DK0927555T3/da active
- 1998-12-21 CZ CZ0425898A patent/CZ299060B6/cs not_active IP Right Cessation
- 1998-12-22 PL PL330496A patent/PL193093B1/pl unknown
- 1998-12-23 TR TR1998/02676A patent/TR199802676A3/tr unknown
- 1998-12-23 NO NO19986089A patent/NO317568B1/no not_active IP Right Cessation
- 1998-12-23 TW TW087121518A patent/TW562675B/zh not_active IP Right Cessation
- 1998-12-23 HU HU9803018A patent/HU227126B1/hu not_active IP Right Cessation
- 1998-12-23 AR ARP980106673A patent/AR012272A1/es not_active Application Discontinuation
- 1998-12-23 ID IDP981688A patent/ID21529A/id unknown
- 1998-12-23 CA CA002257010A patent/CA2257010C/en not_active Expired - Fee Related
- 1998-12-23 NO NO20040145A patent/NO320632B1/no not_active IP Right Cessation
- 1998-12-24 BR BR9805544-5A patent/BR9805544C1/pt not_active Application Discontinuation
- 1998-12-24 CN CNB981116566A patent/CN1149990C/zh not_active Expired - Fee Related
- 1998-12-24 AU AU98225/98A patent/AU745865B2/en not_active Ceased
- 1998-12-24 KR KR10-1998-0058323A patent/KR100432926B1/ko not_active Expired - Fee Related
1999
- 1999-02-21 SA SA99191102A patent/SA99191102B1/ar unknown
2001
- 2001-06-21 IL IL14392101A patent/IL143921A0/xx unknown
2004
- 2004-02-19 KR KR10-2004-0010953A patent/KR100483244B1/ko not_active Expired - Fee Related
- 2004-07-29 US US10/902,249 patent/US20050004109A1/en not_active Abandoned
- 2004-08-13 US US10/918,125 patent/US7745481B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL143921A0 (en)	2002-04-21
CA2257010C (en)	2009-02-17
US6887893B1 (en)	2005-05-03
HUP9803018A2 (hu)	1999-10-28
AU745865B2 (en)	2002-04-11
AU9822598A (en)	1999-07-15
AR012272A1 (es)	2000-09-27
PL193093B1 (pl)	2007-01-31
NZ333399A (en)	2000-05-26
HUP9803018A3 (en)	2000-09-28
KR19990063439A (ko)	1999-07-26
US20050014814A1 (en)	2005-01-20
BR9805544C1 (pt)	2000-06-06
ES2372921T3 (es)	2012-01-27
DK0927555T3 (da)	2012-01-23
ID21529A (id)	1999-06-24
HU227126B1 (en)	2010-07-28
KR100483244B1 (ko)	2005-04-15
TR199802676A2 (tr)	1999-11-22
HK1020261A1 (en)	2000-04-07
NO986089L (no)	1999-06-25
TW562675B (en)	2003-11-21
CZ425898A3 (cs)	1999-07-14
PL330496A1 (en)	1999-07-05
IL143921A (en)	2003-11-23
CA2257010A1 (en)	1999-06-24
EP0927555A1 (en)	1999-07-07
US7745481B2 (en)	2010-06-29
NO20040145L (no)	1999-06-25
CN1230407A (zh)	1999-10-06
NO317568B1 (no)	2004-11-15
BR9805544A (pt)	2000-03-28
CZ299060B6 (cs)	2008-04-16
NO986089D0 (no)	1998-12-23
IL127664A0 (en)	1999-10-28
CN1149990C (zh)	2004-05-19
ATE527022T1 (de)	2011-10-15
EP0927555B1 (en)	2011-10-05
SA99191102B1 (ar)	2006-10-11
NO320632B1 (no)	2006-01-02
KR20040025927A (ko)	2004-03-26
US20050004109A1 (en)	2005-01-06
IL127664A (en)	2003-04-10
HU9803018D0 (en)	1999-02-01
KR100432926B1 (ko)	2004-09-08

Publication	Publication Date	Title
TR199802676A3 (tr)	1999-11-22	Tümörlerin, tümörle ilgili hastaliklarin ve kaseksinin tedavisi ve önlenmesi için yöntem.
NO20005864D0 (no)	2000-11-20	Quinasoler til behandling av hjernesvulst
ZA973105B (en)	1997-12-18	Compounds and methods for the selective treatment of cancer and bacterial infections.
ITTO950104A0 (it)	1995-02-15	Catetere, particolarmente per il trattamento di aritmie cardiache.
ZA971937B (en)	1997-09-08	Combinations for treatment of proliferative diseases.
ZA200108446B (en)	2003-08-27	Novel method of treatment.
ITTO950099A0 (it)	1995-02-14	Catetere, particolarmente per il trattamento di aritmie cardiache.
ZA97631B (en)	1997-08-04	Migraine treatment.
ZA986363B (en)	2000-01-17	Novel method of treatment.
ZA200200606B (en)	2003-01-23	Method of hair treatment using organic amino compounds.
ZA200003236B (en)	2002-01-02	Combination therapy for the treatment of migraine.
ZA985237B (en)	2000-02-17	Novel method of treatment.
MXPA00007394A (es)	2003-08-01	Compuestos, composiciones y metodos para tratar o evitar infeccion de neumovirus y enfermedades asociadas.
AP2004003070A0 (en)	2004-06-30	The method of treating cancer.
WO2001041709A3 (en)	2001-12-13	Methods for treating cell death diseases and inflammation
ZA986364B (en)	2000-01-17	Novel method of treatment.
ZA986365B (en)	2000-01-17	Novel method of treatment.
MXPA03004017A (es)	2004-02-12	Metodo para el tratamiento de inflamacion.
ZA200107523B (en)	2002-11-27	Method for improving the stability of stored and/or light-sensitive therapeutic systems or component thereof.
PT1200447E (pt)	2004-02-27	Oxazinocarbazoles para o tratamento de doencas do snc
ZA977867B (en)	1998-05-27	Method of treatment.
ZA200002338B (en)	2001-11-12	Combination therapy for the treatment of migraine.
ZA200003235B (en)	2002-01-02	Combination therapy for the treatment of migraine.
ZA200007396B (en)	2002-02-27	Method of treatment.
ZA200002343B (en)	2001-11-12	Combination therapy for the treatment of migraine.